health - "study published"

A pediatric bone cancer survivor who now is studying to become a pediatric hematologist/oncologistâ?¦a childhood leukemia survivor who has walked a mile in the shoes of the young cancer patients she now treats. These are just a few of the hundreds of patients treated through the Pediatric Hematology/Oncology program at The Cancer Institute of New Jersey (CINJ), which is celebrating 15 years of patient care this year.

As the Stand Up To cancer campaign -- being put forth by television's 'Big 3' networks -- is opening the nation's eyes to the need and the benefit of cancer research dollars, The Cancer Institute of New Jersey (CINJ) is highlighting some of its groundbreaking studies being conducted by internationally recognized clinical investigators.

Researchers at The University of Texas M. D. Anderson cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-third had tumors that converted from HER2 positive to HER 2 negative status -possibly indicating a resistance to the targeted therapy.

Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson cancer Center. The study, the largest of its kind, was presented in advance of the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, and is the first national study to examine such racial disparities in radiation therapy.

A new study for the Wyoming Department of health says more people quit smoking in communities that have enacted strong laws against smoking in public places.

Obese people who have asthma are nearly five times more likely to be hospitalized for the condition than non-obese people with asthma, according to a Kaiser Permanente study published in the September issue of the Journal of Allergy and Clinical Immunology.

Sepracor Inc. (Nasdaq: SEPR) announced the presentation of LUNESTA ® brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. The poster presentations reflected results from a 12-week, double-blind, randomized safety and efficacy study of 388 elderly patients (65-85 years of age) who were administered either LUNESTA 2 mg or placebo nightly.

QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, announced that it has initiated a second Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of safety and tolerability.

Agile Therapeutics, Inc., announced that it successfully completed two key clinical trials in the development of the company's new, innovative low-dose, once-weekly, contraceptive patch, which the company refers to by its internal product code AG-200-15. The Phase 2b safety and efficacy study successfully met its primary endpoint of ovulation suppression, cycle control and safety.